- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04807855
Custom Print Megnetic Levator Prosthesis Pilot Comparison
Study Overview
Detailed Description
Extensive description of the study protocol is provided in the Research Strategy (R), but key components are summarized and justified here. This is a prospective, interventional, single-arm, single-group open label study. Because the primary objective of this study is to perform prototyping in the interest of developing and determining the feasibility of our novel approach, randomization to treatment or control is not necessary or appropriate at this stage. All participants will have ptosis and will be fitted with the experimental custom adjustable force MLP. Determining if the custom MLP is superior to the non-custom MLP is beyond the scope of this phase I SBIR project.
The primary outcome is custom MLP fitting success defined as 8mm interpalpebral fissure size or greater, patient desire to engage in a 20-min trial, and comfort rated greater than 5 out of 10 after the 20 minute trial (all criteria must be met). These criteria may be met at any one visit in the prototyping process. Therefore, one prototype may fail but if subsequent prototypes succeed, the case will be rated as a success. Selection of the criteria was based on a desire to have both objective and subjective metrics. Eye opening of 8mm was selected because it is a functional amount of eye opening found to be useful to patients in prior studies (note that these patients do not have inferior lid malposition). We have used interpalpebral fissure as a primary outcome as opposed to Marginal Reflex Distance (distance from the corneal reflection to upper lid) in order to allow enrollment of bilateral and severe cases, and to provide a common outcome for both eye opening and closing on the blink. Desire to engage in a 20-minute trial was selected as a criteria because it provides some information on the patient's opinion of the device. Comfort greater than 5 out of 10 indicates better than neutral, and was selected as a minimum goal for success (median comfort in our prior study was 8 out of 10).
The statistical analysis method for the primary outcome will be an exact binomial test of one proportion to determine which condition is met for more than half of patients. If the prototype approach is successful for greater than half of patients after 20 minutes of wear there will be a large enough sample for a phase II study to warrant continued development.
Sample Size Calculation for primary outcome: With 10 subjects we will have 80% power to show that the success rate significantly exceeds 50% with a one-sided alpha=0.05 exact binomial test of one proportion when the success rate is 8/10 or greater, meaning 8 would have to succeed to reach significance. With 15 subjects the success rate would need to be 11 to reach significance.
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02114
- Mass. Eye and Ear
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Presence of Blepharoptosis for at least one eye, moderate cognitive function or better defined as greater than or equal to 18 out of 30 on a pre-screening of the Mini-Mental State Exam, age 5 or older. Sex - All. Gender Based - All.
Exclusion Criteria:
- Absence of Blepharoptosis. Age less than 5, Severe Cognitive impairment defined as Mini-mental score less than 18, behaviors consistent with delirium (combinations of disorientation, hallucinations, delusions, and incoherent speech), or lethargy. These individuals must be excluded since participation requires competent self-care, reliable responses and cooperation during fitting of the devices. Healthy Volunteers.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Device Feasibility
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: the experimental arm
All subjects, the ptosis group and the normal group receive the same intervention.
|
There is only one medical device we are testing, so only one intervention.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Resting interpalpebral fissure size
Time Frame: after 20 minutes of wear
|
Interpalpebral fissure is defined as the greatest distance between the upper and lower eye lid margins at the insertion point of the lashes.
Resting is defined as point where the eyelid is maximally elevated.
|
after 20 minutes of wear
|
Patient decision to participate in a 20-min trial with the prototype MLP
Time Frame: after 2 minutes of wear
|
This is a binary response measure (1 = yes I would like to participate or 0 = no I would not like to participate.
|
after 2 minutes of wear
|
Comfort rating scale
Time Frame: after 20 minutes of wear
|
This measure is a 10 point likert-type rating scale used to quantify the comfort of the MLP (1 poor comfort to 10 high comfort).
|
after 20 minutes of wear
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Difference in the resting interpalpebral fissure size from highest to lowest magnetic force settings
Time Frame: after 2 minutes of wear
|
Interpalpebral fissure is defined as the greatest distance between the upper and lower eye lid margins at the insertion point of the lashes.
Resting is defined as point where the eyelid is maximally elevated.
|
after 2 minutes of wear
|
Interpalpebral fissure size at maximum blink
Time Frame: after 2 minutes, 20 minutes, and 1-week of wear
|
Interpalpebral fissure is defined as the greatest distance between the upper and lower eye lid margins at the insertion point of the lashes.
Maximum blink is the point of smallest interpalpebral fissure (most closing).
|
after 2 minutes, 20 minutes, and 1-week of wear
|
Frequency and severity of adverse events
Time Frame: after 20 minutes and 1-week of wear
|
Thresholds for adverse events include eyelid skin erythema greater than grade II on the industry scale, grade II worsening in corneal staining on the NEI industry scale, and a greater than 2-line worsening in visual acuity in the treated eye.
|
after 20 minutes and 1-week of wear
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Yu Cao, Mr, Skelmet Inc
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Skelmet
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blepharoptosis
-
RVL Pharmaceuticals, Inc.CompletedAcquired BlepharoptosisUnited States
-
Levation Pharma, Ltd.Completed
-
RVL Pharmaceuticals, Inc.CompletedBlepharoptosisUnited States
-
CHU de Quebec-Universite LavalCompleted
-
Cairo UniversityCompleted
-
University of MiamiCompleted
-
RVL Pharmaceuticals, Inc.Completed
-
Rabin Medical CenterUnknown
Clinical Trials on The cMLP device
-
Sanliurfa Mehmet Akif Inan Education and Research...CompletedDepressive Disorder | Restless Legs Syndrome | Anemia of Chronic Kidney Disease | Hemodialysis-Associated Pruritus | Malnutrition-Inflammation-Cachexia SyndromeTurkey
-
Memorial Sloan Kettering Cancer CenterCompleted
-
Darma Inc.Virginia Commonwealth UniversityCompletedVital Sign MonitoringUnited States
-
Endogenex, Inc.Active, not recruitingGlucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Diabetes | Metabolic Disease | Diabetes Type 2United States
-
Queen's UniversityAlexander Medical Inc.Completed
-
phenox Inc.CompletedIschemia | Pathologic Processes | Cardiovascular Diseases | Vascular Diseases | Cerebrovascular Disorders | Brain Diseases | Central Nervous System Diseases | Nervous System Diseases | Stroke, Ischemic | Stroke, AcuteUnited States, Germany
-
University Hospital, BrestRecruiting
-
University of South FloridaMoterum Technologies, Inc.Completed
-
University of South FloridaMoterum Technologies, Inc.Completed